Guggenheim Has Lowered Expectations for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its target price reduced by Guggenheim from $58.00 to $50.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Guggenheim’s price target indicates a potential upside of 44.74% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. boosted their target price on Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. UBS Group reaffirmed a “neutral” rating and issued a $49.00 target price on shares of Bruker in a report on Friday, February 13th. The Goldman Sachs Group decreased their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research report on Friday, February 13th. Finally, Citigroup dropped their price target on Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Bruker currently has a consensus rating of “Hold” and a consensus target price of $49.77.

Bruker Stock Up 2.4%

NASDAQ:BRKR traded up $0.83 during trading hours on Monday, hitting $34.55. 551,864 shares of the company traded hands, compared to its average volume of 2,434,308. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The firm’s 50-day simple moving average is $40.06 and its 200-day simple moving average is $41.29. Bruker has a one year low of $28.53 and a one year high of $56.22. The company has a market cap of $5.26 billion, a PE ratio of -230.28, a PEG ratio of 2.02 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker will post 2.69 earnings per share for the current year.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at $7,064,365. This trade represents a 5.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 11,000 shares of company stock worth $554,280. 27.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bruker

Several institutional investors and hedge funds have recently bought and sold shares of BRKR. Sector Gamma AS grew its stake in shares of Bruker by 28.0% during the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock worth $8,152,000 after acquiring an additional 54,939 shares during the period. Becker Capital Management Inc. raised its stake in Bruker by 606.8% in the 3rd quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after acquiring an additional 258,545 shares during the period. DNB Asset Management AS lifted its holdings in Bruker by 40.5% during the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after purchasing an additional 41,289 shares during the last quarter. Aquatic Capital Management LLC lifted its holdings in Bruker by 120.3% during the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock valued at $11,358,000 after purchasing an additional 190,883 shares during the last quarter. Finally, M&G PLC boosted its position in Bruker by 233.0% during the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock worth $35,079,000 after purchasing an additional 766,992 shares during the period. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.